[
    [
        {
            "time": "2018-01-03",
            "original_text": "Noteworthy ETF Inflows: XLV, JNJ, TMO, LLY",
            "features": {
                "keywords": [
                    "ETF",
                    "Inflows",
                    "XLV",
                    "JNJ",
                    "TMO",
                    "LLY"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Noteworthy ETF Inflows: XLV, JNJ, TMO, LLY",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-04",
            "original_text": "Celgene: Pomalyst and Otezla’s Revenue Trends in 4Q17",
            "features": {
                "keywords": [
                    "Celgene",
                    "Pomalyst",
                    "Otezla",
                    "Revenue",
                    "4Q17"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Celgene: Pomalyst and Otezla’s Revenue Trends in 4Q17",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-05",
            "original_text": "Johnson & Johnson’s Valuation after Its 4Q17 Earnings",
            "features": {
                "keywords": [
                    "Johnson & Johnson",
                    "Valuation",
                    "4Q17",
                    "Earnings"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Johnson & Johnson’s Valuation after Its 4Q17 Earnings",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]